MX2018008771A - Formulaciones/composiciones que comprenden un inhibidor de btk. - Google Patents
Formulaciones/composiciones que comprenden un inhibidor de btk.Info
- Publication number
- MX2018008771A MX2018008771A MX2018008771A MX2018008771A MX2018008771A MX 2018008771 A MX2018008771 A MX 2018008771A MX 2018008771 A MX2018008771 A MX 2018008771A MX 2018008771 A MX2018008771 A MX 2018008771A MX 2018008771 A MX2018008771 A MX 2018008771A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- compositions
- btk inhibitor
- ibrutinib
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621001986 | 2016-01-19 | ||
| PCT/EP2017/050962 WO2017125423A1 (en) | 2016-01-19 | 2017-01-18 | Formulations/compositions comprising a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008771A true MX2018008771A (es) | 2018-11-09 |
Family
ID=57851067
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008771A MX2018008771A (es) | 2016-01-19 | 2017-01-18 | Formulaciones/composiciones que comprenden un inhibidor de btk. |
| MX2024009894A MX2024009894A (es) | 2016-01-19 | 2018-07-17 | Formulaciones/composiciones que comprenden un inhibidor de btk. |
| MX2022006768A MX2022006768A (es) | 2016-01-19 | 2018-07-17 | Formulaciones/composiciones que comprenden un inhibidor de btk. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009894A MX2024009894A (es) | 2016-01-19 | 2018-07-17 | Formulaciones/composiciones que comprenden un inhibidor de btk. |
| MX2022006768A MX2022006768A (es) | 2016-01-19 | 2018-07-17 | Formulaciones/composiciones que comprenden un inhibidor de btk. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190282577A1 (https=) |
| EP (1) | EP3405177B1 (https=) |
| JP (3) | JP7109365B2 (https=) |
| KR (1) | KR20180101521A (https=) |
| CN (1) | CN108472259A (https=) |
| AR (1) | AR107391A1 (https=) |
| AU (2) | AU2017208472B2 (https=) |
| BR (1) | BR112018014590A2 (https=) |
| EA (1) | EA201891440A1 (https=) |
| HK (2) | HK1259440A1 (https=) |
| MA (1) | MA43649A (https=) |
| MX (3) | MX2018008771A (https=) |
| TW (1) | TWI803454B (https=) |
| WO (1) | WO2017125423A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210033067A (ko) | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| US20190290650A1 (en) * | 2016-01-19 | 2019-09-26 | Janssen Pharmaceutic Nv | Formulations/compositions comprising a btk inhibitor |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3523280B1 (en) | 2016-10-06 | 2026-03-11 | Janssen Pharmaceutica NV | Processes and intermediates for preparing a btk inhibitor |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| CA3089537A1 (en) | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
| BR112020024481A2 (pt) | 2018-06-15 | 2021-03-02 | Janssen Pharmaceutica Nv | formulações/composições compreendendo ibrutinib |
| US10688050B1 (en) * | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| CN117064862B (zh) * | 2023-04-10 | 2025-12-19 | 山东新时代药业有限公司 | 一种伊布替尼肠溶片及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| HU227530B1 (en) | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP1664762A4 (en) | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| KR20210033067A (ko) * | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| US20150140085A1 (en) | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| EP2902016A1 (en) * | 2014-01-30 | 2015-08-05 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Febuxostat tablet |
| KR20170033358A (ko) * | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
| CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
-
2017
- 2017-01-18 MX MX2018008771A patent/MX2018008771A/es unknown
- 2017-01-18 US US16/071,448 patent/US20190282577A1/en not_active Abandoned
- 2017-01-18 HK HK19101844.5A patent/HK1259440A1/zh unknown
- 2017-01-18 HK HK19101838.3A patent/HK1259434A1/zh unknown
- 2017-01-18 WO PCT/EP2017/050962 patent/WO2017125423A1/en not_active Ceased
- 2017-01-18 EA EA201891440A patent/EA201891440A1/ru unknown
- 2017-01-18 BR BR112018014590-4A patent/BR112018014590A2/en not_active Application Discontinuation
- 2017-01-18 EP EP17700820.8A patent/EP3405177B1/en active Active
- 2017-01-18 AU AU2017208472A patent/AU2017208472B2/en active Active
- 2017-01-18 JP JP2018537505A patent/JP7109365B2/ja active Active
- 2017-01-18 KR KR1020187023222A patent/KR20180101521A/ko active Pending
- 2017-01-18 MA MA043649A patent/MA43649A/fr unknown
- 2017-01-18 CN CN201780006752.0A patent/CN108472259A/zh active Pending
- 2017-01-19 AR ARP170100141A patent/AR107391A1/es unknown
- 2017-01-19 TW TW106101783A patent/TWI803454B/zh not_active IP Right Cessation
-
2018
- 2018-07-17 MX MX2024009894A patent/MX2024009894A/es unknown
- 2018-07-17 MX MX2022006768A patent/MX2022006768A/es unknown
-
2022
- 2022-04-07 JP JP2022063871A patent/JP2022105009A/ja not_active Withdrawn
- 2022-05-04 US US17/736,305 patent/US20220339157A1/en active Pending
- 2022-11-25 AU AU2022275514A patent/AU2022275514A1/en not_active Abandoned
-
2023
- 2023-10-25 JP JP2023183050A patent/JP2024023184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1259440A1 (zh) | 2019-11-29 |
| JP7109365B2 (ja) | 2022-07-29 |
| JP2019506387A (ja) | 2019-03-07 |
| HK1259434A1 (zh) | 2019-11-29 |
| MX2024009894A (es) | 2024-09-10 |
| JP2024023184A (ja) | 2024-02-21 |
| CA3008338A1 (en) | 2017-07-27 |
| AU2017208472A1 (en) | 2018-07-05 |
| MA43649A (fr) | 2018-11-28 |
| EP3405177A1 (en) | 2018-11-28 |
| AR107391A1 (es) | 2018-04-25 |
| US20190282577A1 (en) | 2019-09-19 |
| US20220339157A1 (en) | 2022-10-27 |
| JP2022105009A (ja) | 2022-07-12 |
| MX2022006768A (es) | 2022-06-17 |
| EP3405177B1 (en) | 2026-03-11 |
| TW201731513A (zh) | 2017-09-16 |
| BR112018014590A2 (en) | 2018-12-11 |
| TWI803454B (zh) | 2023-06-01 |
| AU2017208472B2 (en) | 2022-09-01 |
| CN108472259A (zh) | 2018-08-31 |
| EA201891440A1 (ru) | 2018-12-28 |
| WO2017125423A1 (en) | 2017-07-27 |
| KR20180101521A (ko) | 2018-09-12 |
| AU2022275514A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| ZA201701299B (en) | Glycosidase inhibitors | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
| MY189453A (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders | |
| EA033163B1 (ru) | Ингибиторы глутаминазы | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| TW201625535A (en) | Inhibitors of histone demethylases | |
| WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
| WO2015179823A3 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
| MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GEAP201814255A (en) | P-substituted asymmetric ureas and medical uses thereof | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| UA117524C2 (uk) | Стимулятори рослин, їх застосування та спосіб стимуляції рослин |